Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Immunovia AB ( (SE:IMMNOV) ) just unveiled an update.
Immunovia AB announced interim results from its AFFIRM study, demonstrating that its PancreaSure test achieved 88% sensitivity and 98% specificity in detecting late-stage pancreatic cancer. The study, conducted across Europe and the U.S., supports PancreaSure’s accuracy in identifying both cancerous and healthy samples, building on previous studies and aiming to reassure physicians of its efficacy. The company is also exploring the test’s impact on clinical decision-making, which is crucial for securing reimbursement from insurers.
More about Immunovia AB
Immunovia AB is a diagnostic company focused on increasing survival rates for pancreatic cancer patients through early detection. The company develops and commercializes blood-based tests to detect proteins and antibodies indicating pancreatic cancer in high-risk individuals. Immunovia collaborates with healthcare providers, experts, and advocacy groups to make its tests available, with a significant focus on the U.S. market, where 1.8 million individuals are at high risk for pancreatic cancer.
Average Trading Volume: 10,651,927
Technical Sentiment Signal: Sell
Current Market Cap: SEK157M
See more data about IMMNOV stock on TipRanks’ Stock Analysis page.